Furthermore, with the recent clinical introduction of Fc-engineered antibodies, testing of an affinity-enhanced antibody in a mouse lacking its key FcγR has little value.
Recently, immune competent mice expressing only the human FcγRs have been created. 7 This mouse contains each of the individual hFcγR transgenes (hFcγRI, hFcγRIIA R131 , hFcγRIIB I232 , hFcγRIIIA F158 and hFcγRIIIB) under the control of their endogenous promoters and regulatory elements and has proven to be a critical tool for the evaluation and study of hIgGs in models of infectious disease and syngeneic tumor therapy. 8 However, this model has no ability to engraft human cancers that bear human-specific epitopes that are not shared by mice, nor does transgenic expression of such human epitopes in mouse cancers truly reflect the native expression levels. Therefore, a new mouse model expressing human FcγRs in an immune deficient setting is necessary for better preclinical efficacy testing of therapeutic antibodies.
The first step to establish the new immune deficient 'RHuFR' mice was to cross immunodeficient Rag2 − / − mice that lack mature B and T cells to mouse FcγR knockout mice (mFcγRI − / − , mFcγRα − / − ), 7 creating Rag2 − / − FcγR Null mice ( Figure 1b ). This FcγR Null strain successfully demonstrates the loss of mouse FcγR expression on all leukocyte populations (Supplementary Figure S1 ). This strain was then crossed to the immunocompetent human FcγR+ mice. 7 The product of this breeding was a Rag2 − / − human FcγR+ mouse (RHuFR). Expression of each hFcγR on the mouse leukocyte populations in the novel RHuFR mouse recapitulated the human expression pattern (Supplementary Figure S2 , Supplementary Table S1 ). Furthermore, mice lacking each of the individual hFcγRs were isolated while breeding to create single human FcγR 'knockout' strains in the Rag2 − / − background ( Supplementary Table S2 ). Loss of the B and T cell populations in the FcγR Null, RHuFR and RHuFR 'knockout' strains was also confirmed (Supplementary Figure S3 ).
The newly generated RHuFR mice were first used in a model of idiopathic thrombocytopenia purpura (ITP), as a surrogate for in vivo antibody-dependent cytotoxicity by employing an antiplatelet hIgG1. The RHuFR mice achieved platelet depletion, comparable to what is reported for the immunocompetent human FcγR+ mice 7 (Supplementary Figure S4A ). This suggests that the introduction of Rag2 deficiency does not interfere with FcγR mediated function in these animals and that FcγR function has been maintained from the parental immunocompetent human FcγR+ mice. The RHuFR 'knockout' strains were also used in the ITP model and overall, demonstrated little fluctuation in hFcγR mediated platelet depletion compared to the parental RHuFR strain (Supplementary Figure S4B) .
Next, to investigate the ability of RHuFR mice to more accurately mimic clinical observations for therapeutic cancer antibodies, we chose two commercially available anti-CD20 antibodies, rituximab and obinutuzumab, which substantially differ in human clinical activity. Rituximab contains a wild type hIgG1 heavy chain constant region, while obinutuzumab contains a hIgG1 heavy chain constant region with decreased levels of fucosylated oligosaccharides resulting in enhanced binding to hFcγRIIIA and thus enhanced ADCC activity. A recent Phase III study in patients with CLL demonstrated that the Fc enhanced obinutuzumab confers a significantly higher response rate and survival advantage over rituximab therapy. 9 We first investigated antibody pharmacokinetics. For both antibodies, Rag2 − / − mouse FcγR+ mice had prolonged antibody blood half-lives, while the RHuFR mice had extremely short antibody kinetics (Supplementary Figure S5) . Human FcγRI is the only high affinity human FcγR that binds soluble, monomeric IgG. The high degree of homology between human and mouse FcγRI, as well as their IgG binding affinity suggest that human FcγRI has likely limited contribution to the cytotoxic activity of anti-tumor mAbs in vivo. 6, 10 Indeed, for several therapeutic antibodies, clinical response to therapy has been shown to be associated with SNPs of the low affinity FcγRs, hFcRγIIIA and hFcγRIIA, but not with hFcγRI. Furthermore, mechanistic studies on the role of human FcγRs in the in vivo activity of anti-CD20 antibodies revealed that cytotoxicity against tumor targets is mediated exclusively through hFcγRIIIA-mechanisms.
Therefore, we employed the RHuFR derivative strain that lacks human FcγRI (RHuFR 1 − ) to remedy this kinetic discrepancy (Supplementary Figure S5) , thereby allowing for an antibodydosing regimen to compare therapeutic effects between the RHuFR 1and the Rag2 − / − mouse FcγR+ mice. Importantly, the RHuFR 1mouse expresses all other human FcγRs in the same manner as in the RHuFR mice (Supplementary Figure S6) and is functionally intact, showing identical platelet clearance to the RHuFR mouse in the ITP model (Supplementary Figure S4B ). Furthermore, since the main focus of this study is the generation of mouse strains for the study of Fc effector function in vivo, the humanization of FcRn was not necessary given that FcRn function is to regulate IgG half-life and not effector function.
Rag2 − / − mice expressing either the mouse FcγRs or human FcγRs (RHuFR 1-) were engrafted with the CD20+ Daudi human lymphoma cell line and treated with rituximab or obinutuzumab. The affinities of rituximab and obinutuzumab for the relevant mouse and human FcγRs were measured (Figure 2a , Obinutuzumab therapy resulted in a small reduction in overall tumor burden when compared to untreated mice (P = 0.0072) and no difference in survival was observed between the two anti-CD20 mAb therapy groups. Right two curves show total radiance signal (photons/second) and Kaplan-Meier survival curves for all RHuFR 1mice (n = 9-10 mice/group). Obinutuzumab therapy demonstrated significant reductions in tumor burden compared to untreated and isotype (P o0.0001 for both). There was also a significant difference in overall tumor burden between rituximab and obinutuzumab treated groups (P = 0.003) and a significant survival advantage for obinutuzumab therapy compared to rituximab therapy (P = 0.0088).
Supplementary Figure S7 ). As hFcγRI is not present in the RHuFR 1− mouse strain used, affinity values have been omitted for clarity. The Fc engineering of obinutuzumab results in a significant increase in affinity for hFcγRIIIA, with little to no increase in affinity for activating mouse FcγRs. In the mouse FcγR+ mice, no significant therapeutic response benefit for rituximab was observed, while obinutuzumab resulted in a less than 1 log decrease in overall tumor signal as compared to untreated (P = 0.0072) (Figures 2b and c) . However, obinutuzumab therapy did not confer a survival advantage over rituximab therapy in the mouse FcγR+ mice (Figure 2c) .
In contrast, rituximab modestly slowed lymphoma growth in the RHuFR 1mice, while obinutuzumab achieved significant eradication of the lymphoma with a~1 vs~2 log reduction in tumor burden from untreated, respectively (Figures 2b and c) . Moreover, by Day 28, 9/10 mice on obinutuzumab therapy had no detectable tumor burden, while only 4/10 mice on rituximab therapy showed no detectable tumor (Supplementary Figure S8) . Both rituximab and obinutuzumab treatment resulted in increased median survival compared to untreated and isotype treated mice (Figure 2c ). Moreover, a significant survival advantage for obinutuzumab vs rituximab treated RHuFR 1mice was seen. These data directly mimic the enhanced human clinical response rates and prolonged progression free survival trends observed for obinutuzumab over rituximab. 9 Furthermore, these data support the importance of testing Fc enhanced therapeutic antibodies in the setting of the human FcγR network.
In contrast to the traditional immunodeficient model with mouse FcγRs, the RHuFR 1mice reproduced the clinical observations for rituximab vs obinutuzumab therapy. In addition, the RHuFR derivative strains lacking one or more hFcγRs will allow for the probing of the individual roles of each receptor in both pharmacology and therapy, as demonstrated in the inflammatory ITP model. This is especially important to quickly identify the receptors responsible for mAb therapy in vivo and subsequently direct Fc engineering of the antibody. Furthermore, crossing these RHuFR 'knockout' strains can quickly create mice containing combinations of human FcγR 'knockouts' for probing receptor interactions and redundancy in function. Overall, these mice are tools to expand our understanding of the complexity of the human FcγR network and how individual antibody targets (for example, epitope, target cell type, microenvironment and so on) can greatly shape the observed therapeutic effect for a given antibody.
